Lourdes M. Mendez

Hematology
330 Brookline Ave
Boston, MA 02215

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 44 publications

Menin inhibitors for patients with relapsed/refractory acute myeloid leukemia (AML): a systematic review and meta-analysis.

Menin inhibitors for patients with relapsed/refractory acute myeloid leukemia (AML): a systematic review and meta-analysis.

Journal: Leukemia & lymphoma
Published: June 07, 2026

Cost-effectiveness of frontline eltrombopag with immunosuppressive therapy for severe aplastic anemia.

Cost-effectiveness of frontline eltrombopag with immunosuppressive therapy for severe aplastic anemia.

Journal: Blood. Red cells & iron
Published: May 04, 2026

Thrombo-inflammatory endothelial signatures in JAK2 -mutated myeloproliferative neoplasms.

Thrombo-inflammatory endothelial signatures in JAK2 -mutated myeloproliferative neoplasms.

Journal: bioRxiv : the preprint server for biology
Published: February 27, 2026

A Phase Ib/II study of ceralasertib, a selective inhibitor of ATR, in patients with relapsed or refractory MDS and CMML.

A Phase Ib/II study of ceralasertib, a selective inhibitor of ATR, in patients with relapsed or refractory MDS and CMML.

Journal: Blood advances
Published: January 23, 2026

Acute myeloid leukemia after myeloproliferative neoplasms: Real-world outcomes in the new treatment era in the United States.

Acute myeloid leukemia after myeloproliferative neoplasms: Real-world outcomes in the new treatment era in the United States.

Journal: Cancer
Published: January 21, 2026

Clinical Trial Patient Matching: A Real-Time, Common Data Model and Artificial Intelligence-Driven System for Semiautomated Patient Prescreening in Cancer Clinical Trials.

Clinical Trial Patient Matching: A Real-Time, Common Data Model and Artificial Intelligence-Driven System for Semiautomated Patient Prescreening in Cancer Clinical Trials.

Journal: JCO clinical cancer informatics
Published: January 09, 2026

Hypomethylating agents plus venetoclax versus intensive chemotherapy prior to transplant in high-risk acute myeloid leukemia.

Hypomethylating agents plus venetoclax versus intensive chemotherapy prior to transplant in high-risk acute myeloid leukemia.

Journal: Haematologica
Published: November 10, 2025

Feasibility, safety and outcomes of patients with newly diagnosed acute myeloid leukemia discharged 'early' after intensive induction.

Feasibility, safety and outcomes of patients with newly diagnosed acute myeloid leukemia discharged 'early' after intensive induction.

Journal: Leukemia & lymphoma
Published: October 29, 2025

Author Correction: An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancer.

Author Correction: An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancer.

Journal: Nature genetics
Published: October 22, 2025

Isavuconazole provides effective and tolerable antifungal prophylaxis for patients with acute myeloid leukemia.

Isavuconazole provides effective and tolerable antifungal prophylaxis for patients with acute myeloid leukemia.

Journal: Leukemia research
Published: October 08, 2025

Comparative effectiveness of HMA with venetoclax vs intensive chemotherapy in AML with very high-risk cytogenetics.

Comparative effectiveness of HMA with venetoclax vs intensive chemotherapy in AML with very high-risk cytogenetics.

Journal: Blood neoplasia
Published: September 18, 2025

Clinicopathological Challenge: Fixed Urticaria-Like Pink Papules in a Patient With Recurrent Fevers and Arthralgias.

Clinicopathological Challenge: Fixed Urticaria-Like Pink Papules in a Patient With Recurrent Fevers and Arthralgias.

Journal: International journal of dermatology
Published: July 14, 2025
Showing 1-12 of 44

Last Updated: 09/26/2026